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Abstract: Cancer organoids are 3D phenotypic cultures that can be established from resected or
biopsy tumour samples and can be grown as mini tumours in the dish. Flourishing evidence supports
the feasibility of patient derived organoids (PDO) from a number of solid tumours. Evidence for
cholangiocarcinoma (CCA) PDO is still sparse but growing. CCA PDO lines have been established
from resected early stage disease, advanced cancers and highly chemorefractory tumours. Cancer
PDO was shown to recapitulate the 3D morphology, genomic landscape and transcriptomic profile of
the source counterpart. They proved to be a valued model for drug discovery and sensitivity testing,
and they showed to mimic the drug response observed in vivo in the patients. However, PDO lack
representation of the intratumour heterogeneity and the tumour-stroma interaction. The efficiency
rate of CCA PDO within the three different subtypes, intrahepatic, perihilar and distal, is still to be
explored. In this manuscript we will review evidence for CCA PDO highlighting advantages and
limitations of this novel disease model.
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1. Introduction
Organoids are microscopic three-dimensional (3D) tissue-like structures that outgrow from
primary tissue explants or from single cells. Advances in 3D culturing techniques enabled the
expansion of single stem cells into self-organizing tissues that functionally recapitulate key aspects of
their in vivo tissue of origin [1]. Stem cell organoids can mimic the stem cell niche and can be derived
from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and tissue resident adult stem
cells (ASCs) Figure 1. While ESC- and iPSC-derived organoids recapitulate embryonic developmental
processes, organoids derived from ASCs represent a diversity of organotypic cultured tissues [1,2],
where tissue homeostasis, or its disruption during disease, is recapitulated. This technology is
commonly based on the use of 3D culture systems characterized by the presence of a basal membrane,
acting as an extracellular matrix (ECM), and growth factors. Once embedded in ECM, these cells
self-assemble and differentiate in response to physical and molecular cues giving rise to 3D constructs
that genotypically and phenotypically recapitulate the in vivo counterpart. The work that opened
the avenue to organotypic culture was published in 2009 by Sato et al. [3]. Through this study they
explored how the combination of a laminin-rich basal membrane (Matrigel) and a cocktail of growth
factors (including the Epidermal Growth factor, R-spondin 1 and Noggin) gave rise to gut epithelial
organotypic constructs with villus-crypt structures starting from a single mouse Lgr5+ intestinal
stem cell [3]. Since then, a plethora of different human and mouse organoid cultures have been
established [4–8], and are now used as 3D ex vivo models of a number of organs and diseases.
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Figure 1. Organoids establishment from different cell sources and their downstream applications.
Organoids can be originated from different sources: ESCs, ASCs, iPSCs and primary tissue.
The embedding of these cells in a basal membrane (BM), mostly represented by Matrigel, with
appropriate growth factors has been reported to give rise to cholangiocytes [9] intestinal [3],
hepatobiliary [10] organoids and lung [7]. For the capability to recapitulate 3D architecture, genotype
and the histomorphology of the in vivo counterpart these constructs can be exploited for (a) disease
modelling, (b) drug screening and precision medicine. Given their genome stability and the possibility
to establish an organotypic culture with patient cells, organoids also showed to be a promising tissue
source for regenerative medicine (c).
2. Hepatobiliary Organoids
During the last decade it has been possible to observe an exponential growth in organoid
research. Nevertheless, liver organoids remain poorly represented compared to organotypic constructs
resembling other organs. Despite this, first attempts to create 3D liver tissues had already been reported
at the beginning of this century. Particularly, Michalopoulos et al. were able to bring more insights
about the tissue organization of liver through a culture system characterized by roller bottles whose
internal surfaces were covered with collagen [11]. Isolating hepatocytes from rat liver though the
collagenase perfusion technique and culturing them for 20 days with a medium including hepatocyte
growth factor (HGF), epidermal growth factor (EGF) and dexamethasone they observed a 3D sheets-like
construct with the surface facing the medium characterized by a biliary epithelium, and the layer below
comprising of hepatocytes embedded in connective tissue and in contact with a layer of endothelial
cells. Through this approach they reported how the dexamethasone was essential for the maturation
of hepatocytes, since the absence of this molecule in culture caused a reduction of up to 15% of
immature Hepar+ and cytochrome p-450+ hepatocytes; conversely, the combination of HGF and EGF
was essential for the maturation of the biliary epithelium and for the development of the connective
tissue. Likewise, Doffou et al. showed the role of other genes, such as OCT4, in the hepatocyte-biliary
transdifferentiation. Inhibition of this factor induced the incapacity of biliary cells facing the medium
to complete their transition from hepatocytes to biliary cells [12]. To date, it is still elusive of which cells
in the liver serve as the cell-of-origin for the organoids. Animal experiments showed that when all liver
tissue was dissociated and cultured in Matrigel, there was a preponderance of cholangiocytes markers
(cytokeratin 19, CK19) over hepatocyte markers (albumin, ALB). Likewise, deprivation of Noggin
and Jagged-1 in the media for organoid propagation induced a higher ratio of CK19/ALB, suggesting
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that progenitor cells might commit to biliary differentiation under 3D culture [13]. The theory of cell
plasticity is also confirmed by the evidence that an organoid line established from an intrahepatic
cholangiocarcinoma (iCCA) patient-derived xenograft (PDX) displayed a hepatocyte-like phenotype
when culture with the appropriate differentiation medium used for human liver organoids. Wnt
pathway deregulation and epigenetic control seemed to be the driving forces for the switch from iCCA
to the hepatocyte phenotype [14]. Similarly, spheroids from human induced hepatocytes (generated
from umbilical cord fibroblasts) could be differentiated into hepatocellular carcinoma (HCC) through
Myc activation or into iCCA thorugh Kirsten Rat Sarcoma (KRAS) activation [15]. The development
of 3D culture systems based on the use of Matrigel as artificial ECM brought more sophisticated
studies on liver organogenesis. Wu et al. 2019 were able promote the development of hepatobiliary
organoids starting from human induced pluripotent stem cells (hiPSCs) in 45 days [16]. Notch appears
to act as a driving factor for the biliary morphogenesis [16,17]. Addition of a NOTCH inhibitor in the
culture medium led to the total absence of mature ductal structures, with a significant decrease of
transcription factors regulating cholangiocytes’ differentiation, such as HNF6 and Sox9 [17]. Genome
stability and maintenance of tissue identity over long term expansion opened the possibility of applying
hepatobiliary organoids in regenerative medicine [18,19]. Huch et al. reported an increased genome
stability in ASC derived organoids compared to organoids derived from reprogrammed iPSCs [18].
Normal liver ASC derived organoids accumulate between 63 and 139 base substitution per culture,
which appears to be 10-fold less compared to the liver iPSC-derived organoids [18,20]. Sampaziotis et
al. demonstrated how extrahepatic cholangiocytes organoids continued to express biliary markers in
98% of cases after 20 passages, while they also maintain their functional extrusion capabilities [19].
Different attempts to apply this technology in vivo have been reported. Hu et al. showed that human
hepatocyte-derived organoids engrafted in immune compromised mice with damaged liver can give
rise to repopulation and proliferation over a period of 90 days with final cell population expressing
functional maturity markers ALB, MRP2 and CYP2E1 [21]. Sampaziotis et al. cultured human primary
extrahepatic cholangiocytes’ organoids (ECO) and showed that, when seeded in a biocompatible
scaffold, were able to reconstruct an injured tract of the biliary tree in vivo [19]. Although more work
needs to be carried out, these studies could open a new avenue to develop novel applications in
regenerative medicine. Since the cells are established directly from the donor, these methods have the
potential to avoid possible rejections in transplantation medicine.
3. Cancer Patient Derived Organoids
Cancer models are used in basic research to unveil mechanisms of cancer development and
progression and to identify vulnerabilities that can be exploited for cancer therapeutics. Cancer
cell lines (CCLs) derived from human cancer tissues have been widely used for many years to
model cancer phenotypes in vitro. CCLs are grown as two-dimensional (2D) cultures and have
advantages such as an ease of culture with the possibility to grow over time, a lack of need for
elaborate media, fast growth rate and suitability to high-throughput drug screening and functional
experiments. At the same time, this model has several limitations such as the low efficiency to establish
cell lines from the origin tumour due to the reduced adaptation of cells in the new environment, and
loss of identity over time with the potential accumulation of new molecular aberrations due to the
proliferation capacity combined with several passages required in culture. Furthermore, CCLs do not
recapitulate the conditions observed in vivo such as cell-to-cell interaction, cell-to-ECM interplay and
tumour-to-microenvironment crosstalk that is known to be crucial for cell function and drug response.
Tumour spheroids are 3D clusters of cells that form as the result of the tendency of adherent cells to
aggregate when grown in suspension. They were demonstrated to be an improved model over CCLs
to mimic drug response/resistance due to their potential to recapitulate cellular layered assembling,
hypoxia and nutrient gradients [22]. However, they lack the histomorphology and 3D-architecture of
human tumours. Animal models are more useful when a phenotype needs to be studied in vivo and
the contribution of the microenvironment requires to be addressed. In an attempt to reproduce and
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conserve the patient tumour characteristics (such as heterogeneous histology, malignant phenotypes
and genotypes, tumour architecture and vasculature) patient-derived xenografts (PDX) have been
established [23,24]. PDX are models based on the engraftment of cancer cells or small pieces of tumour
tissue orthotopically or subcutaneously in immunocompromised mice. After the engraftment, cancer
cells or tissues undergo a vascularization process allowing a more physiological environment. This
model has shown to be remarkably useful, especially for drug testing, because it allows researchers
to mimic the response in vivo to a given drug. However, this model has several drawbacks: it
lacks the immune system and the original surrounding stromal cells; it is time consuming, highly
expensive and not suitable for high-throughput screening Table 1. Patient derived organoids (PDO)
have filled the gap between CCLs/spheroids and PDX as powerful tools to study tumour morphology
and functionality, while taking into consideration cell-to-cell and cell-to-ECM interactions, to allow
systematic chemical and genetic perturbation combined with in toto imaging of 3D tumour tissues
over time. Improvements of protocols for 3D organotypic cultures allowed researchers to obtain cancer
organoids directly from patient biopsy material providing individualized cancer models that reproduce
interpatient heterogeneity [25,26]. Histological analysis showed that these constructs retained the
microscopic features and histomorphologic architecture observed in the tumour source. Similarly,
molecular characterization confirmed that the mutational landscape of the original tumour is retained
in the PDO [25,26].
Table 1. Comparison of the main cancer models considering time, cost, establishment success rate,
robustness, high throughput suitability and main limitations.
Comparison 2D Cancer Cell Lines(CCLs) Tumour Spheroids
Patient-Derived
Organoids (PDO)
Patient-Derived
Xenografts (PDX)
Time Days Days Weeks Several Months
Cost Low Low Medium Expensive
Establishment
success rate
Low:
poor adaptation of
patient-derived cells to
in vitro culture
conditions
High Medium-High Tumour type dependent
Robustness
Low:
lacking of cell–cell
interaction, cell–ECM
interaction and absence
of tumour
microenvironment cause
a misestimation in
therapy prediction
Medium:
recapitulate cell–cell
interaction; more reliable
model in therapy
prediction compared to
2D cell lines
High:
resemble
morphologically,
genomically and
histologically the tissue
of origin; reported as
powerful preclinical
in vitro model (with a
high predictive value) to
predict patient-specific
therapy response
High:
recapitulate the realistic
tumour environment
with the establishment of
vasculature after
engraftment; this allows
to use PDX as in vivo
preclinical models to
evaluate patient-specific
therapy response with a
high predictive value
High
throughput
drug screening
suitability
Suitable Suitable Suitable Not suitable
Main
limitations
Tend to accumulate
mutations and to lose
their identity with cell
passages; do not
recapitulate the
microenvironment
conditions observed
in vivo (presence of
stroma cells, immune
system and blood
vessels)
Do not recapitulate
histological and
morphological features
of the tumour tissue; lack
of original stroma and
vasculature components
Lack of original stroma
and vasculature
components
Lack of a natural tumour
microenvironment;
presence of recipient
stroma cells to the
engraftment site; do not
allow to reproduce
crucial interactions
(stroma-immune cells,
immune cells-tumour)
4. Cholangiocarcinoma Patient-Derived Organoids (CCA PDO)
Cholangiocarcinomas (CCAs) are aggressive and heterogeneous malignancies arising from the
biliary tree and, based on the anatomical location, can be categorized in intrahepatic (iCCA), perihilar
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(pCCA) and distal (dCCA). Only 20% of patients undergo surgery, while the majority of CCA patients
are diagnosed at an advanced stage. Evidence of CCA PDO is still sparse Figure 2. Broutier et al.
established long term cultures of primary liver cancer organoids from treatment-naïve resected
specimens of three subtypes of liver cancer [4]. As normal liver cell populations are known to give
rise to liver organoids, the issue of normal liver outgrowth was targeted using a tumoroid-specific
medium lacking R-sponding-1, Noggin and Wnt3a [18]. The efficiency of PDO establishment seemed
to correlate with the proportion of proliferating cells requiring at least 5% proliferative index in the
tumour sample. As seen for other tumour types, these PDO maintained histological features (with
EpCam+ positivity for iCCA), expression profiles and marker expression of the parental tissue (keratin
7 for iCCA) after long term expansion in culture. Taking advantage of the whole cohort of primary
liver cancers (HCC = 3; iCCA = 2 and mixed HCC/CCA = 2) and the cohort of normal liver organoids,
Broutier et al. derived a liver tumoroid gene signature. Resected early stage liver cancers have been
extensively studied and molecularly characterized [27–31]. However, gene expression profiles of
tumour organoids allowed identification of a further 11 genes that had never previously been reported
associated with liver cancer before and had prognostic value, with a specific value for C1QBP for
iCCA. Given the tumoroids recapitulated the morphological and functional aspects of the source
tissues, differences between HCC and iCCA were retained ex vivo at all levels. If PDO from resected
specimens contribute to provide further disease models to investigate biology and test drug sensitivity,
their application is limited in clinical practice as the majority of patients are diagnosed at an advanced
stage. Lampis et al. provided the first evidence that PDO can be established from biopsies of advanced
iCCA patients who failed more than one chemotherapy line [32]. The combination of PET-scan and
CT-guided fine needle biopsy was used to identify the tumour area responsible for disease progression,
thus generating a model of highly chemoresistant CCA. Not only the PDO did retain the morphological
architecture of human CCA with glandular domain, and genomic profiles of the source tissue, but
also displayed a similar drug-resistance in line with the chemoresistance shown in the patient, thus
offering a clinically relevant platform for drug discovery. Indeed, these PDO were used to validate
data from drug discovery projects providing an additional layer in the preclinical assessment of novel
therapeutics. In addition, PDO have the advantage of being a flexible tool where drug efficacy can be
tested in association with biomarker development through PDO genomic manipulation that is feasible
and effective [32]. Lampis et al. were able to show a positive correlation between MIR21 expression
and resistance to Heat Shock Protein 90 inhibitors via a controlled lentiviral transcriptional activation
of the miRNA ex vivo (PDO) and in vivo (PDO-derived PDX) [32]. Similarly, Artegiani et al. have used
genomic manipulation of normal cholangiocytes’ organoids to recreate the genetic background of CCA.
Electroporation protocols enabled transfection of CRISPR/Cas9 vectors inducing frameshift mutations
in both alleles of the BAP1 gene. The 3D nature of organoids allowed identification of the role of BAP1
in maintenance of the epithelium integrity and cell polarity, which was also confirmed in orthotopic
liver transplantation of genetically engineered organoid lines [33]. Similarly, genetic manipulation
of murine liver and gallbladder organoids allowed the investigation of the oncogenic potential of a
number of molecular aberrations, showing that KRAS may have a role in tumour initiation, while
other alterations, such as PIK3CA mutation and FGFR fusions, occur later in tumour progression and
have less tumorigenic potential [13,34]. Saito et al. derived four biliary cancer patient PDOs, including
three iCCAs and one gallbladder cancer (GBC), all established from early stage resected tumours [5].
Interestingly, they were able to show that the growth kinetics differ between organoids derived from
tumour and normal tissue. While cancer organoids can be kept in culture for a long time (>1 year) and
easily expanded after freezing without morphological changes, organoids derived from non-cancer
gallbladder and bile duct tissues showed a higher proliferation rate at the early passages but ceased
to proliferate after passage 15. As expected, the genomic profile of CCA PDO were different from
non-cancer bile duct organoids, in terms of both the coding and non-coding transcriptome [5].
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Figure 2. Patient derived organoid (PDO) lines from biliary tract malignancies. Graphic representation
of four types of biliary tract malignancies with relative PDO lines generated so far for GBC [5] and
iCCA (from top to bottom of the box [4,5,14], [32], [35], [36]). (N: number of patients; n: number of
PDO lines).
5. Applications of Patient Derived Organoids in CCA
CCA PDO recapitulate the 3D architecture, morphology, genotype and phenotype of human
CCA, while they can be easily manipulated and as such, they provide a valuable tool for functional
characterization of CCA behaviour. Compared to animal models they are faster and cheaper offering
the opportunity to create a large biobank of PDO lines that can be used to reproduce ex vivo the
heterogeneity of CCA subtypes. Nonetheless, PDO have several limitations in comparison to animal
models, which we will address in the next chapter. Thus, it is likely that for an appropriate expansion
of CCA knowledge a combination of several models will be more useful than relying on one specific
model. As described earlier, PDO represent a relevant model to assess drug response and promote a
drug discovery project associated to biomarker development. Novel genes have been identified to
maintain CCA growth over normal counterpart, suggesting that PDO can help in the identification
of novel targets for therapeutic development that potentially target the 3D growth of CCA and the
cell-to-cell and the cell-to-ECM interactions [4]. Furthermore, this technology is amenable to identify
markers associated with drug sensitivity/resistance and to carry out de-novo high-throughput drug
screening to identify new effective drugs with reduced adverse side effects. Saito et al. and Van de
Wetering et al. reported that cancer-derived organoids sensitivity to nutlin 3a is associated with the
status of TP53 [5,37]. Saito et al. tested a library of 339 compounds in clinical use in biliary cancer PDO
and observed 22 drugs that successfully inhibited the growth of organoids. Among these there were
two antifungal compounds (amorolfine and fenticonazole), which suppressed iCCA organoids’ growth,
while not causing significant toxicity to normal biliary epithelial cells [5]. Moreover, PDO can be used in
animal models, injected subcutaneously or orthotopically, to generate PDO-derived PDX. Subcutaneous
injection of CCA PDO in NSG mice have enabled the study of tet-on tet-off gene modulation in an in vivo
model that maintains the same phenotype as of the human source tumour [32]. PDO generated from
liver biopsies of colorectal cancer were shown to reproduce in the liver of NSG mice the same growth
and drug response pattern observed in human [26]. Specifically, PDO from Regorafenib-sensitive
patients showed a vessel co-option growth pattern, while PDO from Regorafenib-progressing patients
manifested a desmoplastic pushing histopathological growth patterns in line with data observed in
human patients [38]. This suggests that PDO may be able to reproduce the cancer-to-microenvironment
interactions in vivo and that PDO-derived PDX could serve as an appropriate model to investigate
mechanisms of resistance to agents targeting the microenvironment. Human CCA poses a remarkable
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challenge in the clinical oncological management. In an era where precision oncology is the central
focus of oncological treatments, molecular characterization of advanced biliary cancers becomes
one of the main challenges due to the following issues: 1) conversely to liver biopsies that usually
provide enough tissue for molecular studies in iCCA, fine needle biopsies of pCCA and dCCA may
pose some limitations for a mutational profile [39]. Nonetheless the positive experience of precision
oncology in CCA has been mainly focused on iCCA with FGFR or IDH alterations (Moscato trial);
2) it is becoming more and more evident that phenotypic changes play an important role for the drug
response, which adds to the information gathered from the somatic mutational profile. In order to
perform a comprehensive molecular characterization at different levels (DNA, RNA and proteins) more
tissue is needed, and single biopsies may not be sufficient. CCA PDO represent a useful tool to expand
the epithelial cancer component and to allow the application of a wide range of different technologies
that would not otherwise be possible. This application would also enable gathering information on
advanced CCA, comparing how advanced CCA may differ and evolve from early stage resected CCA
that have been characterised so far, and understanding the contribution of the molecular heterogeneity
in cancer progression with regards to the different CCA subtypes. In addition, PDO offer the possibility
to optimize and enhance precision oncology by underpinning a programme of individualized oncology.
Recent evidence has shown that PDO can mimic ex vivo and in vivo responses observed in the patient
opening the way to use PDO as a platform to guide therapeutic decisions [26]. PDO can be grown
in a clinically meaningful time ranging between 6 and 10 weeks, maintain the same genotypic and
phenotypic profile in the culture and has a positive and negative predictive value of 88% and 100%,
respectively, in predicting the response in the patient [26]. Interestingly, Vlachogiannis et al. showed
how the value of PDO in predicting the drug response goes beyond molecularly targeted drugs and
can be applied to chemotherapy drugs or multityrosine kinases for which a molecular predictive
biomarker has not been identified to date [26]. Information obtained through these approaches offer
the possibility to have a genomic and drug-response profile for each patient and aid the selection
of second line treatment by avoiding unnecessary toxicities and impacting on the quality of life of
CCA patients.
6. Limitations of Patient Derived Organoids
Cancer PDO has shown to be a promising model to aid tumour biology understanding and
precision oncology. However, there are still several open issues that need to be addressed before their
use can be widely applied and their potential be implemented in clinical practice. We can foresee three
main checkpoints in a successful PDO culture: 1) the establishment step with a PDO line growing
within the first 2–4 weeks, 2) the ability to re-expand after splitting and 3) the capacity to grow back
after cryopreservation. Several authors have shown that the efficacy rate of gastrointestinal cancer
PDO to overcome all the three checkpoints is around 70% [26,40,41]. Unfortunately, the evidence
for CCA PDO is still too sparse to be able to validate these findings. In our experience, PDO from
highly chemoresistant CCA could grow in 5–6 weeks to a stage where functional analyses were
possible [32]. Saito et al. reported a low efficiency rate, which seemed dependent on the subtype
of biliary tumour (50% for iCCA and 20% for other biliary cancers). However, tumour PDO for
which long term culture failed, did not harbour any driver gene mutations, raising the possibility
that cultures were established from the contaminating non-cancerous cells [5]. In addition, some of
the differences may be due to the early stage vs. advanced disease status. PDO success rate seems
to be influenced by cellularity [4,26]; thus, PDO from extrahepatic biliary cancers were thought to
be more challenging than iCCA. Unfortunately there is not enough data to confirm or refute this
hypothesis; however Tiriac et al. have recently shown that the efficiency rate of PDO from pancreatic
cancer fine needle biopsies is 70% [41]; given the diagnostic pathway of pancreatic cancer is very
close to that of extrahepatic biliary cancers, it is sensible to speculate that access to tissues should
not represent a limiting factor in pCCA and dCCA PDO. Cancer PDO reproduces 3D morphological
structures that resemble the histological architecture of the source tumour. They comprise of cancer
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cells that have the ability to reshape within the ECM base and form glandular or tubular structures;
however, they lack the microenvironment components and over time, despite maintaining their 3D
morphology, they become pure epithelial cancer 3D cell lines. This may represent a remarkable
limitation given the recent promise of therapies manipulating the tumour infiltrating immune cells.
In order to overcome this challenge either co-cultures or air–liquid interphase (ALI) organoid models
have been developed. Neal et al. generated ALI PDO from resected and metastatic tumours [42].
Continued growth >100 days did not always maintain complex tissue architecture suggesting that
this method is more suitable for the purpose of a “live drug sensitivity platform” than long term
disease modelling. Immune cells tended to decrease over 1 month of culture but could be preserved
for longer with the addition of interleukin-2 [42]. Interestingly, the tumour infiltration lymphocytes
within the PDO recapitulated the TCR repertoire of the original tumour, and preserved the ability
to induce an antitumour immune response in plastic [42]. Likewise, co-cultures of cancer PDO with
different components of the microenvironment have been successful. Dijkstra et al. co-cultured PDO
prestimulated with Interferon γ with autologous T cells from peripheral blood lymphocytes [43].
Interestingly, they observed a tumour-specific T cell response when the co-cultures were established
from mismatch deficient tumour PDO, while no activity was observed in the case of MHC class I
deficient lines [43]. There is growing evidence showing that cancer is a heterogeneous disease with a
number of clones that can outgrow and provide growth advantage over others. PDO derive from a
core of tissue and, as such is subjected to sampling bias. PDO derived from multiple samples within
the same tumour has confirmed that PDO recapitulate the intratumour heterogeneity in colorectal
cancer [26]. Data on the intratumour heterogeneity of CCA is limited. Li et al. established 17 PDO lines
from three resected patients with iCCA and reported that less than 30% of the variance in the drug
response is due to intratumour heterogeneity [35]. Thus, more studies are needed to understand the
level of intratumour heterogeneity of CCA and how much this issue can represent a limiting factor in
biliary cancer. Recent efforts have tried to derive a protocol for the generation of PDO from circulating
tumour cells (CTC) [44]. The efficiency rate reported so far is quite low and mainly positive in diseases
with a high burden of CTC such as prostate cancers [25]. Moreover, CCA have shown to have a limited
number of EpCam+ CTC, limiting this technology in its current form [45].
7. Conclusions
PDO are promising new tools to model CCA. They can mimic the cell-to-cell interaction, the
cell-to-ECM interplay and the drug sensitivity of human cancers. More recent evidence suggests that
co-cultures of PDO with various components of the microenvironment is feasible and help to establish
mini organs on a chip that can better recapitulate the complexity of human disease. Multiple evidences
suggest that PDO can be established from CCA patients. However, more studies are needed in order
to understand the efficiency rate of CCA PDO in clinical practice, their differentiation according to the
subtype and their potential clinical applicability.
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